Celgene (CELG) Given a $128.00 Price Target at Mizuho

Mizuho set a $128.00 price objective on Celgene (NASDAQ:CELG) in a research report released on Tuesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the company. William Blair restated an outperform rating on shares of Celgene in a research note on Friday, October 20th. BidaskClub raised Celgene from a sell rating to a hold rating in a report on Tuesday, December 12th. Citigroup reaffirmed a hold rating on shares of Celgene in a report on Friday, December 22nd. Leerink Swann reaffirmed a buy rating and issued a $156.00 price target on shares of Celgene in a report on Friday, October 20th. Finally, Deutsche Bank assumed coverage on Celgene in a report on Tuesday, December 12th. They issued a hold rating and a $114.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $133.95.

Shares of Celgene (NASDAQ CELG) traded down $2.51 during trading on Tuesday, hitting $104.46. The stock had a trading volume of 5,919,752 shares, compared to its average volume of 4,822,178. The firm has a market capitalization of $83,720.00, a price-to-earnings ratio of 24.64, a PEG ratio of 0.82 and a beta of 1.77. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. Celgene has a 12 month low of $94.55 and a 12 month high of $147.17.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. Celgene’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.58 earnings per share. equities analysts anticipate that Celgene will post 6.68 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in CELG. Thompson Davis & CO. Inc. grew its stake in shares of Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the last quarter. Arcadia Investment Management Corp MI increased its stake in Celgene by 118.7% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares during the last quarter. Robecosam AG purchased a new stake in Celgene in the 3rd quarter valued at about $114,000. Guidant Wealth Advisors purchased a new stake in Celgene in the 3rd quarter valued at about $119,000. Finally, Capital Bank & Trust Co increased its stake in Celgene by 166.8% in the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 517 shares during the last quarter. 79.74% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.com-unik.info/2017/12/27/celgene-celg-given-a-128-00-price-target-at-mizuho-2.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

What are top analysts saying about Celgene? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit